Last reviewed · How we verify

N-acetylcysteine and deferoxamine

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude · Phase 2 active Small molecule

N-acetylcysteine and deferoxamine is a Small molecule drug developed by Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude. It is currently in Phase 2 development.

At a glance

Generic nameN-acetylcysteine and deferoxamine
SponsorUniversidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about N-acetylcysteine and deferoxamine

What is N-acetylcysteine and deferoxamine?

N-acetylcysteine and deferoxamine is a Small molecule drug developed by Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude.

Who makes N-acetylcysteine and deferoxamine?

N-acetylcysteine and deferoxamine is developed by Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude (see full Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude pipeline at /company/universidade-do-extremo-sul-catarinense-unidade-academica-de-ciecias-da-saude).

What development phase is N-acetylcysteine and deferoxamine in?

N-acetylcysteine and deferoxamine is in Phase 2.

Related